Positive beta-amyloid PET scans were key inclusion criteria in the trials that led to the approval of Aduhelm, which is designed to target and remove beta-amyloid plaques in people with Alzheimer's disease. Yet, amyloid PET scans are not mentioned on the drug's label as a requirement for prescribing it, SNMMI stated.
Aduhelm is the first drug that targets the underlying pathology of Alzheimer's disease rather than its symptoms. It was approved June 7 by the U.S. Food and Drug Administration.
Copyright © 2021 AuntMinnie.com